Prodrugs

Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Health sciences, Health care, Antiviral drugs, Orphan drugs, Brincidofovir, Ebola, Prodrugs, Biopharmaceutical, Glioma

DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 10:55 a.m.

Key Points: 
  • DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 10:55 a.m.
  • Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.
  • ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and an efficacy analysis by blinded independent central review is expected later in 2021.

Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021

Retrieved on: 
Thursday, July 29, 2021
Drugs, Antiviral drugs, Brincidofovir, Ebola, Prodrugs, Infectious diseases, Medical specialties, Smallpox

ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update.

Key Points: 
  • ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update.
  • A live audio webcast of the call will also be available on the Investors section of the Company's website, www.chimerix.com .
  • An archived webcast will be available on the Chimerix website approximately two hours after the event.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.

New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

Retrieved on: 
Wednesday, July 14, 2021
Blood, Hematology, Health, Drugs, Orphan drugs, Coagulation system, Fostamatinib, Organophosphates, Prodrugs, Hemostasis, Thrombosis, Thrombocythemia

All ePosters will be made available online during the Poster Networking Session on the conference website on Saturday, July 17, 2021, at 4:00 p.m. Eastern Time.

Key Points: 
  • All ePosters will be made available online during the Poster Networking Session on the conference website on Saturday, July 17, 2021, at 4:00 p.m. Eastern Time.
  • Incidence of bleeding events and use of rescue therapy continually decreased in these 58 patients over the first year of treatment with fostamatinib.
  • Findings include:
    A reduced need for office visits due to oral administration, easy titration, and low incidence of thrombocytosis.
  • Fostamatinib's unique mechanism of action provide increased hemostasis and may reduce the risk of thrombosis.

Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia

Retrieved on: 
Tuesday, July 13, 2021
Cancer treatments, Drugs, Clinical medicine, Acute myeloid leukemia, 7+3, Doxorubicin, Anthracycline, Leukemia, Bisantrene, Prodrugs, Chemotherapy regimen

Annamycin is the Company's next-generation anthracycline that has demonstrated a lack of cardiotoxicity in recently conducted human clinical trials for the treatment of AML.

Key Points: 
  • Annamycin is the Company's next-generation anthracycline that has demonstrated a lack of cardiotoxicity in recently conducted human clinical trials for the treatment of AML.
  • Additionally, Annamycin has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin.
  • This amendment will allow us to continue dose escalation in the Phase 1 portion of the trial and establish the maximum tolerated dose as we work toward the recommended dose for the Phase 2 portion of the study.
  • Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis

Retrieved on: 
Thursday, July 1, 2021
Psychoactive drugs, Drugs, Euphoriants, Heroin, Morphinans, Morphine, Opioids, Prodrugs

An adult subject, aged 63, was enrolled and four 100cm2 treatment areas were identified.

Key Points: 
  • An adult subject, aged 63, was enrolled and four 100cm2 treatment areas were identified.
  • Each treatment area was assigned to receive repeat doses of 4.0x109 PFU (n=2 treatment areas) or 1.0x1010 PFU (n=2 treatment areas).
  • Repeated topical doses of KB105 were well tolerated, and no drug-related adverse effects were reported.
  • However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Government of Canada helping expand access to safer supply across Canada

Retrieved on: 
Monday, June 28, 2021
Psychoactive drugs, Drugs, Euphoriants, Heroin, Morphinans, Morphine, Opioids, Prodrugs

The Government of Canada continues to support increasing access to safer supply services in communities across Canada to help prevent drug overdoses during the pandemic and beyond.

Key Points: 
  • The Government of Canada continues to support increasing access to safer supply services in communities across Canada to help prevent drug overdoses during the pandemic and beyond.
  • Through this funding, the London InterCommunity Health Centre, a leader in the field of safer supply, will bring together community health organizations, primary care teams, private practice providers and federally funded safer supply projects across Canada to build expertise in the delivery of safer supply services.
  • The "National Safer Opioid Supply Community of Practice" project will facilitate the sharing of resources and best practices, helping to expand access to safer supply including in rural, remote and under-resourced areas.
  • The need for safer supply programs has never been clearer, and Health Canada has recognized this need by committing itself to funding a National Safer Supply Community of Practice.

Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference

Retrieved on: 
Thursday, June 24, 2021
Glucocorticoids, Organ systems, Medicine, Medical specialties, Prodrugs, Pregnanes, Muscular dystrophy, Diols, Vamorolone, Prednisone, Dystrophy, Duchenne

The study also demonstrated superiority of both vamorolone dose levels (2 and 6mg/kg/day) versus placebo across multiple secondary endpoints.

Key Points: 
  • The study also demonstrated superiority of both vamorolone dose levels (2 and 6mg/kg/day) versus placebo across multiple secondary endpoints.
  • Vamorolone did not stunt growth, as validated in the current 24-week study, in which vamorolone 6mg/kg/day versus prednisone 0.75mg/kg/day showed a significant difference in growth velocity (p=0.02).
  • The primary endpoint of the study is TTSTAND velocity at 24 weeks comparing the 6mg/kg/day dose of vamorolone to placebo.
  • ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders.

Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day

Retrieved on: 
Wednesday, June 23, 2021
Drugs, Organic compounds, Bristol-Myers Squibb, Chloroarenes, Clopidogrel, Hepatotoxins, Prodrugs, Sanofi, Chemical compounds

Presentations will highlight Jounces productive discovery engine and platform, updates on its discovery pipeline, and progress on the clinical development of JTX-8064.

Key Points: 
  • Presentations will highlight Jounces productive discovery engine and platform, updates on its discovery pipeline, and progress on the clinical development of JTX-8064.
  • More specifically, we will discuss the monotherapy dose escalation status of our INNATE trial of JTX-8064.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

Codeine (CAS 76-57-3) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021
Health, General Health, Drugs, Morphinans, Branches of biology, Opiates, Secondary metabolites, Antidiarrhoeals, Codeine, Prodrugs

The "Codeine (CAS 76-57-3) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Codeine (CAS 76-57-3) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Codeine.
  • The fifth chapter deals with Codeine market trends and forecast, distinguish Codeine manufacturers and suppliers.
  • The Codeine global market report key points:

KIYATEC Clinical Study Data Shows Test Accurately Predicts Brain Cancer Patient Response to Standard Drug Therapy Prior to Treatment

Retrieved on: 
Thursday, June 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health, Medicine, Oncology, Cancer treatments, Lactams, Prodrugs, Temozolomide, Teratogens, Ovarian cancer, Neuro-Oncology, Clinical trial

The results, the interim data analysis of the companys 3D-PREDICT clinical study , were published June 16, 2021 in Neuro-Oncology Advances 1, an open access clinical journal.

Key Points: 
  • The results, the interim data analysis of the companys 3D-PREDICT clinical study , were published June 16, 2021 in Neuro-Oncology Advances 1, an open access clinical journal.
  • The 3D-PREDICT study met this goal early, at its interim data analysis, an achievement that is uncommon for innovations in oncology.
  • KIYATECs test results accurately identified the patients as future temozolomide responders or future non-responders prior to the initiation of drug treatment.
  • In newly diagnosed ovarian cancer patients, KIYATECs test prospectively and accurately predicted response to first-line chemotherapy with 89% accuracy.